Skip to Main Content

Dozens of U.S. lawmakers sent sharply worded letters to the Trump administration and the pharmaceutical industry trade group to demand drug makers stop threatening to curtail discounts provided to a federal program for safety-net hospitals.

The bipartisan effort comes in response to recent steps taken by at least five large drug companies to reduce discounts they offer to the 340B drug discount program. Created in 1992, the program requires drug makers to offer discounts that are typically estimated to be 25% to 50% — but could be much higher — on all outpatient drugs to hospitals and clinics that serve indigent populations.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED